Nanologica's main owner Flerie Invest AB ("Flerie") has acquired additional shares in Nanologica AB with the result that a mandatory bid obligation has arisen. Flerie's total holding in Nanologica after the acquisition amounts to 38,222,779 shares, which corresponds to approximately 43.26 percent of the total number of shares and votes in the company.
According to the Swedish Securities Council's statement AMN 2024:62, Flerie was granted an exemption from the obligation to make a mandatory bid that could arise as a result of Flerie (i) subscribing its share in the rights issue of units that Nanologica carried out in 2024, and (ii) utilised the warrants acquired through the rights issue for share subscription. According to the exception, an obligation to make a mandatory bid arises if Flerie subsequently acquires additional shares and thereby increases its voting rights in Nanologica.
According to a press release from Flerie AB (parent company of Flerie Invest AB) on April 25, Flerie intends to revert with information about a possible public takeover bid regarding the remaining shares in Nanologica within four weeks.
For further information, please contact
Gisela Sitbon
Chairman of the board
Ph: +46 70 282 55 58 or e-mail: gisela@sitbon.nu
About Nanologica AB (publ)
Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica's products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica's share (NICA) is listed for trading on Nasdaq Stockholm Main Market. For further information, please visit www.nanologica.com.
